SCHEMBL2938955

SCHEMBL2938955

CCC(CC)C(=O)N1CCC2(CC1)N[C@H](Cc1ccccc1)C(=O)N2Cc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 1/20 0.42
CCR5 P51681 6/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CACNA1G O43497 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SIGMAR1 Q99720 2/20 0.36
SLC6A12 P48065 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1800476 1.00 CXCR3 (0.42) CXCR3CCR5MEN1KMT2ACACNA1G
SCHEMBL2938951 1.00 CXCR3 (0.42) CXCR3CCR5MEN1KMT2ACACNA1G
Hydrochloric Acid SCHEMBL1800981 0.99 CXCR3 (0.41) CXCR3CCR5MEN1KMT2ACACNA1G
SCHEMBL1800769 0.94 CXCR3 (0.41) CXCR3CCR5GAAL3MBTL1
SCHEMBL2934997 0.94 CXCR3 (0.41) CXCR3CCR5GAAL3MBTL1
Hydrochloric Acid SCHEMBL1800156 0.93 CCR5 (0.41) CXCR3CCR5MEN1KMT2AGAA
SCHEMBL1801540 0.89 CYP2D6 (0.41) CXCR3CCR5MEN1KMT2ASIGMAR1
SCHEMBL2940899 0.89 CYP2D6 (0.41) CXCR3CCR5MEN1KMT2ASIGMAR1
SCHEMBL2940902 0.89 CYP2D6 (0.41) CXCR3CCR5MEN1KMT2ASIGMAR1
Hydrochloric Acid SCHEMBL1800899 0.89 CYP2D6 (0.41) CXCR3CCR5MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO claimed
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP claimed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP disclosed
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO disclosed
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP disclosed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO disclosed